Temozolomide

Phase 1Terminated

0 views this week 0 watching💤 Quiet

Interest: 15/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Glioma

Conditions

Glioma

Trial Timeline

Apr 17, 2017 → Jul 27, 2020

NCT ID

NCT02507232

About Temozolomide

Temozolomide is a phase 1 stage product being developed by Novocure for Glioma. The current trial status is terminated. This product is registered under clinical trial identifier NCT02507232. Target conditions include Glioma.

What happened to similar drugs?

0 of 3 similar drugs in Glioma were approved

Approved (0) Terminated (0) Active (3)

🔄Everolimus + ONC201Jazz PharmaceuticalsPhase 3

🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3

🔄safusidenib + PlaceboNuvation BioPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03705351	Phase 1	Terminated	Dec 2, 2019	Feb 24, 2022	Glioblastoma
NCT03477110	Phase 1	Completed	May 4, 2018	Jan 26, 2024	Glioblastoma
NCT03232424	Phase 1	Completed	Jul 26, 2017	Dec 7, 2022	Glioblastoma, Adult
NCT03780569	Pre-clinical	UNKNOWN	Apr 27, 2017	Jan 1, 2019	Glioblastoma Multiforme
NCT02507232	Phase 1	Terminated	Apr 17, 2017	Jul 27, 2020	Glioma
NCT00916409	Phase 3	Completed	Jun 1, 2009	Mar 1, 2017	Glioblastoma Multiforme

Competing Products

20 competing products in Glioma

See all competitors

Product	Company	Stage	Hype Score
Enzastaurin (LY317615) + Carboplatin	Eli Lilly	Phase 1	29
LY2157299 + Lomustine	Eli Lilly	Phase 1	29
DS-1001b	Daiichi Sankyo	Phase 2	39
DS-1001b	Daiichi Sankyo	Phase 1	33
Perampanel + Standard of Care	Eisai	Phase 1/2	32
Temozolomide and Bevacizumab	Eisai	Phase 2	31
Temozolomide	Eisai	Phase 2	31
Gliadel Wafer + Temozolomide	Eisai	Phase 2	31
Palonosetron (PALO)	Eisai	Phase 2	35
Gliadel/Avastin/CPT-11	Eisai	Phase 2	27
Lenvatinib + Bevacizumab	Eisai	Phase 2	35
Granisetron + Ondansetron	Kyowa Kirin	Phase 2	27
Binimetinib 15 MG	Ono Pharmaceutical	Phase 2	42
Enzastaurin	Eli Lilly	Phase 2	35
Pembrolizumab + Pemetrexed + Abemaciclib	Eli Lilly	Phase 1	21
LY2157299 + Radiation + Temozolomide	Eli Lilly	Phase 1/2	32
Abemaciclib + Temozolomide	Eli Lilly	Phase 2	39
DSP-0390	Sumitomo Pharma	Phase 1	36
DSP-0390	Sumitomo Pharma	Phase 1	33
Apatinib	Jiangsu Hengrui Medicine	Phase 2	31